{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '11.5.1.5. Concomitant Medications', 'Concomitant medications will be documented for each patient. A detailed history of medications', 'will be documented. At each study visit, patients will be asked whether they have taken any', 'medication other than the study treatment. All concomitant medications including dietary', 'supplements, over-the-counter medications, and oral herbal preparations, as well as changes in', 'medication, will be recorded in the eCRFs.', 'Necessary supportive care, such as appetite stimulants, anti-emetics, anti-diarrheals, etc. is', 'allowed (see Table 16 and Section 10.3).', '11.5.1.6. Adverse Events', 'Information regarding AEs and SAEs will be collected. See Section 12.', '11.5.2.', 'Laboratory Safety Assessments', '11.5.2.1. Clinical Laboratory Tests', 'Table 19 presents the clinical laboratory tests that will be performed during the study.', 'Table 19:', 'Clinical Laboratory Tests', 'Complete Blood Count with Differential (Blood sample: whole blood + EDTA)', 'Hemoglobin', 'Hematocrit', 'Mean corpuscular', 'Mean corpuscular', 'Mean corpuscular', 'volume', 'hemoglobin', 'hemoglobin', 'concentration', 'WBC count', 'WBC differentiala', 'RBC count', 'Lymphocytes', 'Monocytes', 'Neutrophils', 'Eosinophils', 'Basophils', 'Platelets', 'Complete Serum Chemistry (Blood sample: serum)', 'Sodium', 'Potassium', 'Chloride', 'Bicarbonate', 'Urea or blood urea', 'nitrogenb', 'Creatinine', 'Glucose', 'Calcium', 'Phosphate', 'Magnesium', 'ALT', 'AST', 'Alkaline Phosphatase', 'Total bilirubin', 'Total protein', 'Albumin', 'Creatine kinase', 'Urate', 'Coagulation', 'Prothrombin time', 'International', 'Activated', 'normalized ratio', 'thromboplastin time', 'Urinalysis', 'Appearance', 'Color', 'Glucose', 'Hemoglobin', 'Ketones', 'pH', 'Protein', 'Specific gravity', 'Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; EDTA =', 'ethylenediaminetetraacetic acid; RBC = red blood cell; ULN = upper limit of normal; WBC = white blood cell.', 'a', 'WBC differential may be automated or manual as per institutional standards. Reticulocytes may be done only', 'when clinically indicated.', 'b', 'Urea (mg/dL) = Blood urea nitrogen (mg/dL) X 2.14.', 'c', 'Microscopy will only be performed if clinically indicated.', 'Confidential', 'Page 83', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'All laboratory safety assessments will be performed and analyzed at each site by a certified local', 'laboratory. The Investigator or designee will review the laboratory results and assess the clinical', 'significance of all abnormal values. Appropriate action will be taken for any clinically significant', 'abnormal values. Values will be documented on the laboratory report until stabilized, or the', 'laboratory value returns to a clinically acceptable range (regardless of relationship to study', 'treatment) or baseline.', 'In addition, laboratory safety assessments will be performed and analyzed on the scheduled day,', 'even if study treatment is being withheld. More frequent assessments may be performed if', \"clinically indicated or at the Investigator's discretion and these should be recorded in the\", 'Unscheduled Visit eCRFs if medical decisions are made based on the results of these tests.', 'Any laboratory value that remains abnormal at the EoT Visit and that is considered clinically', 'meaningful will be followed according to accepted medical standards for up to 30 days or until', 'resolution of the abnormality or return to baseline. Toxicity will be graded using NCI CTCAE', 'V 4.03.', 'Karyopharm must be provided with a copy of the laboratory certification and normal ranges for', 'each parameter measured. In addition, if at any time a patient has laboratory parameters obtained', 'from a different outside laboratory, Karyopharm must be provided with a copy of the', 'certification and normal ranges for that laboratory.', '11.5.2.2. Pregnancy Testing', 'For females of childbearing potential, a negative serum human chorionic gonadotropin (hCG)', 'pregnancy test must be obtained within 3 days before the first dose of study treatment. Test', 'sensitivity for hCG must be >25 mIU/mL. Pregnancy testing (serum hCG or urine) is also', 'required for females of childbearing potential prior to dosing on Day 1 of Cycles >2 while on', 'treatment (a negative pregnancy test must be documented prior to administration of study drug)', 'and at the EoT Visit (serum hCG).', 'Pregnancy testing may also be performed as clinically indicated during the study.', '11.6.', 'QoL Assessments', 'Quality of life (QoL) will be assessed using the following instruments: EORTC-QLQ-CIPN20,', 'CCI', 'The EORTC QoL instruments and manuals are available on', 'the EORTC QoL website at the following uniform resource locator (URL):', 'http://groups.eortc.be/qol/. The EQ-5D-5L QoL instrument and manual are available on the', 'EuroQol website at the following URL: http://www.eurogol.org.', 'The EORTC-QLQ-CIPN20 is a 20-item QoL instrument, which has been developed to elicit', \"patients' experience of symptoms and functional limitations related to CIPN. The CIPN20 has\", '3 subscales: a sensory, motor, and autonomic subscale.', 'CCI', 'Confidential', 'Page 84', 'Version 4.0']\n\n###\n\n", "completion": "END"}